Neurodevelopmental Outcomes of Very Low Birth Weight Preterm Infants Treated With Poractant Alfa versus Beractant for Respiratory Distress Syndrome

Abstract

Background Some controlled trials have shown significant differences in short-term clinical outcomes between poractant alfa and beractant in infants with respiratory distress syndrome (RDS). There is, however, no study showing the differences in long-term outcomes with these treatments.

Aim To determine and compare the neurodevelopmental outcomes of preterm infants with RDS treated with poractant alfa or beractant at 2 years of age.

Methods This was a prospective, longitudinal, single-center cohort study of infants born at ≤1,500 g and/or ≤32 weeks between 2008 and 2009 who received either poractant alfa (n = 113) or beractant (n = 102) for RDS. Neurological and developmental assessments were performed at a corrected age of 18 to 24 months.

Results About 33 of 113 infants (29.2%) in the poractant alfa group had neurodevelopmental impairment compared with 36 of 102 (35.2%) in the beractant group, and the results did not differ between the groups (p = 0.339). Similarly, no significant difference was found in the percentage of infants with cerebral palsy (11.5 vs. 16.7%, respectively; p = 0.275).

Conclusion Our findings suggest that poractant alfa and beractant are similar in terms of neurodevelopmental outcomes when used for the treatment of RDS in preterm infants.

Keywords

respiratory distress syndrome - poractant alfa - beractant - neurodevelopmental outcome

• References

• 1 Anderson PJ, Doyle LW. Cognitive and educational deficits in children born extremely preterm. Semin Perinatol 2008; 32 (1) 51-58
• 2 Aylward GP. Neurodevelopmental outcomes of infants born prematurely. J Dev Behav Pediatr 2005; 26 (6) 427-440
• 3 Lemons JA, Bauer CR, Oh W, Korones SB, Papille LA, Stoll BJ , et al. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1995 through December 1996. NICHD Neonatal Research Network. Pediatrics 2001; 107 (1) E1
• 4 Ramanathan R. Choosing a right surfactant for respiratory distress syndrome treatment. Neonatology 2009; 95 (1) 1-5
• 5 Seger N, Soll R. Animal derived surfactant extract for treatment of respiratory distress syndrome. Cochrane Database Syst Rev 2009; (2) CD007836
• 6 Suresh GK, Soll RF. Lung surfactants for neonatal respiratory distress syndrome: animal-derived or synthetic agents?. Paediatr Drugs 2002; 4 (8) 485-492
• 7 Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K. North American Study Group. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol 2004; 21 (3) 109-119
• 8 Malloy CA, Nicoski P, Muraskas JK. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr 2005; 94 (6) 779-784
• 9 Gerdes JS, Seiberlich W, Sivieri EM , et al. An open label comparison of calfactant and poractant alfa administration traits and impact on neonatal intensive care unit resources. J Pediatr Pharmacol Ther 2006; 11 (2) 92-100
• 10 Singh N, Hawley KL, Viswanathan K. Efficacy of porcine versus bovine surfactants for preterm newborns with respiratory distress syndrome: systematic review and meta-analysis. Pediatrics 2011; 128 (6) e1588-e1595
• 11 Ramanathan R. Animal-derived surfactants: where are we? The evidence from randomized, controlled clinical trials. J Perinatol 2009; 29 (Suppl. 02) S38-S43
• 12 Barbarello-Andrews L, Marsh W. Pharmacoeconomics of surfactant therapy. J Pediatr Pharmacol Ther 2006; 11 (3) 153-160
• 13 Marsh W, Smeeding J, York JM, Ramanathan R, Sekar K. A cost minimization comparison of two surfactants-beractant and poractant alfa-based upon prospectively designed, comparative clinical trial data. J Pediatr Pharmacol Ther 2004; 9 (2) 117-125
• 14 Dizdar EA, Sari FN, Aydemir C , et al. A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome. Am J Perinatol 2012; 29 (2) 95-100
• 15 Bayley N. Bayley Scales of Infant Development II. San Antonio, TX: Psychological Corp; 1993
• 16 Hagberg B, Hagberg G, Olow I, von Wendt L. The changing panorama of cerebral palsy in Sweden. VII. Prevalence and origin in the birth year period 1987-90. Acta Paediatr 1996; 85 (8) 954-960
• 17 Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978; 92 (4) 529-534
• 18 Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am 1986; 33 (1) 179-201
• 19 Ramanathan R, Bhatia JJ, Sekar K, Ernst FR. Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, alfactant or beractant: a retrospective study. J Perinatol 2013; 33 (2) 119-125
• 20 Fujii AM, Patel SM, Allen R, Doros G, Guo CY, Testa S. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome. J Perinatol 2010; 30 (10) 665-670
• 21 Sinn JK, Ward MC, Henderson-Smart DJ. Developmental outcome of preterm infants after surfactant therapy: systematic review of randomized controlled trials. J Paediatr Child Health 2002; 38 (6) 597-600
• 22 Auten RL, Merzbach J, Myers G, Goldstein RF, Palumbo D. Neurodevelopmental and health outcomes in term infants treated with surfactant for severe respiratory failure. J Perinatol 2000; 20 (5) 291-294
• 23 Moya F, Sinha S, Gadzinowski J , et al; SELECT and STAR Study Investigators. One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics 2007; 119 (6) e1361-e1370
• 24 Robertson B, Curstedt T, Tubman R , et al; Collaborative European Multicentre Study Group. A 2-year follow up of babies enrolled in a European multicentre trial of porcine surfactant replacement for severe neonatal respiratory distress syndrome. Eur J Pediatr 1992; 151 (5) 372-376
• 25 Shankaran S, Johnson Y, Langer JC , et al. Outcome of extremely-low-birth-weight infants at highest risk: gestational age < or = 24 weeks, birth weight < or =750.  g, and 1-minute Apgar < or =3. Am J Obstet Gynecol 2004; 191 (4) 1084-1091
• 26 Moster D, Lie RT, Markestad T. Joint association of Apgar scores and early neonatal symptoms with minor disabilities at school age. Arch Dis Child Fetal Neonatal Ed 2002; 86 (1) F16-F21
• 27 McCrea HJ, Ment LR. The diagnosis, management, and postnatal prevention of intraventricular hemorrhage in the preterm neonate. Clin Perinatol 2008; 35 (4) 777-792 , vii
• 28 O'Shea TM, Allred EN, Kuban KC , et al; ELGAN Study Investigators. Intraventricular hemorrhage and developmental outcomes at 24 months of age in extremely preterm infants. J Child Neurol 2012; 27 (1) 22-29
• 29 Morris BH, Smith KE, Swank PR, Denson SE, Landry SH. Patterns of physical and neurologic development in preterm children. J Perinatol 2002; 22 (1) 31-36
• 30 Vollmer B, Roth S, Baudin J, Stewart AL, Neville BG, Wyatt JS. Predictors of long-term outcome in very preterm infants: gestational age versus neonatal cranial ultrasound. Pediatrics 2003; 112 (5) 1108-1114
• 31 Fanaroff AA, Stoll BJ, Wright LL , et al; NICHD Neonatal Research Network. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol 2007; 196 (2) e1-e8